1. Home
  2. ARGX
Logo argenx SE

ARGX

argenx SE

as 05-29-2024 4:00pm EST

$
-
-
-
.
-
-
+$
-
-
.
-
-
+
-
.
-
-
%

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.

Founded: 2008 Country:
Netherlands
Netherlands
Employees: N/A City: N/A
Market Cap: 22.4B IPO Year: 2017
Target Price: $511.44 AVG Volume (30 days): 264.7K
Analyst Decision: Strong Buy Number of Analysts: 19
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -5.59 EPS Growth: N/A
52 Week Low/High: $327.73 - $550.76 Next Earning Date: 05-09-2024
Revenue: $39,481,111 Revenue Growth: -92.85%
Revenue Growth (this year): 5207.74% Revenue Growth (next year): 37.43%

ARGX Daily Stock ML Predictions

Share on Social Networks: